تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
14.34 US$
+0.35 US$ · +2.50%
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
الإغلاق السابق
14.34 US$
+0.35 US$ · +2.50%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
نطاق اليوم
السعر الحالي 14.34 US$
نطاق 52 أسبوعًا
السعر الحالي 14.34 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
57
قيمة عادلة
المشاعر
56
مختلط
المخاطر
45
مخاطر أعلى من المعتاد
الزخم
52
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
نطاق اليوم
السعر الحالي 14.34 US$
نطاق 52 أسبوعًا
السعر الحالي 14.34 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 |
|---|---|---|
| الإيرادات | 31.89 مليون USD | 20.46 مليون USD |
| الربح الإجمالي | 31.89 مليون USD | 20.46 مليون USD |
| البحث والتطوير | 224.7 مليون USD | 175.31 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 42.26 مليون USD | 42.09 مليون USD |
| نفقات التشغيل | 266.96 مليون USD | 217.4 مليون USD |
| دخل الفوائد | 13.66 مليون USD | 18.12 مليون USD |
| مصاريف الفوائد | 1.14 مليون USD | 2.12 مليون USD |
| الاستهلاك والإطفاء | 13.18 مليون USD | 15.35 مليون USD |
| الدخل التشغيلي | −235.07 مليون USD | −196.94 مليون USD |
| صافي الدخل | −203.15 مليون USD | −173.77 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
ARK Genomic Revolution ETFARKG21.99 مليون1.07%1.56 مليار USD0.75%51.30 US$+4.08%
Vanguard Morningstar Total Stock Market ETFVTI12.47 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM9.06 مليون0.01%78.27 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF4.59 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
JPMorgan U.S. Tech Leaders ETFJTEK4.01 مليون0.08%4.9 مليار USD0.65%107.91 US$+1.80%
ALPS Medical Breakthroughs ETFSBIO2.34 مليون1.22%191.36 مليون USD0.50%55.04 US$+2.03%
iShares Russell 2000 Growth ETFIWO2.2 مليون0.02%13.97 مليار USD0.24%356.78 US$+0.94%
Vanguard Russell 2000 ETFVTWO2.15 مليون0.01%18 مليار USD0.06%112.66 US$+0.50%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFJPMorgan U.S. Tech Leaders ETFJTEKALPS Medical Breakthroughs ETFSBIOiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
